Skip to main content
Erschienen in: Inflammopharmacology 2/2024

06.02.2024 | Original Article

The effects of probiotic supplements on oxidative stress and inflammation in subjects with mild and moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled study

verfasst von: Camellia Akhgarjand, Zahra Vahabi, Sakineh Shab-Bidar, Aliarash Anoushirvani, Kurosh Djafarian

Erschienen in: Inflammopharmacology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Through modulating effects on the gut-brain axis, probiotics are an effective adjuvant treatment for Alzheimer’s disease (AD), one of our century’s most important medical care challenges (Agahi et al. Front Neurol 9:662, 2018). This trial aimed to examine the effects of two different single-strain probiotics on oxidative stress and inflammation in patients with mild and moderate AD. This was a 12-week placebo-controlled, double-blind, randomized clinical trial performed on 90 patients with AD. Eligible patients were randomly assigned to two different interventions (Lacticaseibacillus rhamnosus HA-114 (7.5 × 109) or Bifidobacterium longum R0175 (7.5 × 109)) and a placebo group, supplemented twice daily. We used mixed-effect models to examine the probiotic’s independent effects on clinical results. Significant improvements in serum inflammatory and oxidative stress markers were observed at the end of the trial (P < 0.05). Probiotic supplementation for 12 weeks had beneficial effects on oxidative stress, inflammation, quality of life, and physical activity in patients with mild and moderate AD.
Literatur
Zurück zum Zitat Agahi A, Hamidi GA, Daneshvar R, Hamdieh M, Soheili M, Alinaghipour A et al (2018) Does severity of Alzheimer’s disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front Neurol 9:662CrossRefPubMedPubMedCentral Agahi A, Hamidi GA, Daneshvar R, Hamdieh M, Soheili M, Alinaghipour A et al (2018) Does severity of Alzheimer’s disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front Neurol 9:662CrossRefPubMedPubMedCentral
Zurück zum Zitat Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR et al (2016) Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci 8:256CrossRefPubMedPubMedCentral Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR et al (2016) Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci 8:256CrossRefPubMedPubMedCentral
Zurück zum Zitat Akhgarjand C, Vahabi Z, Shab-Bidar S, Etesam F, Djafarian K (2022) Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer’s disease: a randomized, double-blind, and placebo-controlled study. Front Aging Neurosci 14:1032494CrossRefPubMedPubMedCentral Akhgarjand C, Vahabi Z, Shab-Bidar S, Etesam F, Djafarian K (2022) Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer’s disease: a randomized, double-blind, and placebo-controlled study. Front Aging Neurosci 14:1032494CrossRefPubMedPubMedCentral
Zurück zum Zitat Arora K, Green M, Prakash S (2020) The microbiome and Alzheimer’s disease: potential and limitations of prebiotic, synbiotic, and probiotic formulations. Front Bioeng Biotechnol 8:537847CrossRefPubMedPubMedCentral Arora K, Green M, Prakash S (2020) The microbiome and Alzheimer’s disease: potential and limitations of prebiotic, synbiotic, and probiotic formulations. Front Bioeng Biotechnol 8:537847CrossRefPubMedPubMedCentral
Zurück zum Zitat Athari Nik Azm S, Djazayeri A, Safa M, Azami K, Djalali M, Sharifzadeh M et al (2017) Probiotics improve insulin resistance status in an experimental model of Alzheimer’s disease. Med J Islam Repub Iran 31:103CrossRefPubMedPubMedCentral Athari Nik Azm S, Djazayeri A, Safa M, Azami K, Djalali M, Sharifzadeh M et al (2017) Probiotics improve insulin resistance status in an experimental model of Alzheimer’s disease. Med J Islam Repub Iran 31:103CrossRefPubMedPubMedCentral
Zurück zum Zitat Athari Nik Azm S, Djazayeri A, Safa M, Azami K, Ahmadvand B, Sabbaghziarani F et al (2018) Lactobacilli and bifidobacteria ameliorate memory and learning deficits and oxidative stress in β-amyloid (1–42) injected rats. Appl Physiol Nutr Metab 43(7):718–726CrossRefPubMed Athari Nik Azm S, Djazayeri A, Safa M, Azami K, Ahmadvand B, Sabbaghziarani F et al (2018) Lactobacilli and bifidobacteria ameliorate memory and learning deficits and oxidative stress in β-amyloid (1–42) injected rats. Appl Physiol Nutr Metab 43(7):718–726CrossRefPubMed
Zurück zum Zitat Bolengo F (2023) The intersecting worlds of Alzheimer's disease and Gut Microbiota: a narrative review Bolengo F (2023) The intersecting worlds of Alzheimer's disease and Gut Microbiota: a narrative review
Zurück zum Zitat Bonfili L, Cecarini V, Cuccioloni M, Angeletti M, Berardi S, Scarpona S et al (2018) SLAB51 probiotic formulation activates SIRT1 pathway promoting antioxidant and neuroprotective effects in an AD mouse model. Mol Neurobiol 55(10):7987–8000CrossRefPubMedPubMedCentral Bonfili L, Cecarini V, Cuccioloni M, Angeletti M, Berardi S, Scarpona S et al (2018) SLAB51 probiotic formulation activates SIRT1 pathway promoting antioxidant and neuroprotective effects in an AD mouse model. Mol Neurobiol 55(10):7987–8000CrossRefPubMedPubMedCentral
Zurück zum Zitat Cammann D, Lu Y, Cummings MJ, Zhang ML, Cue JM, Do J et al (2023) Genetic correlations between Alzheimer’s disease and gut microbiome genera. Sci Rep 13(1):5258CrossRefPubMedPubMedCentral Cammann D, Lu Y, Cummings MJ, Zhang ML, Cue JM, Do J et al (2023) Genetic correlations between Alzheimer’s disease and gut microbiome genera. Sci Rep 13(1):5258CrossRefPubMedPubMedCentral
Zurück zum Zitat Chen X-X, Zeng M-X, Cai D, Zhou H-H, Wang Y-J, Liu Z (2023) Correlation between APOE4 gene and gut microbiota in Alzheimer’s disease. Benef Microbes 14(4):349–360CrossRef Chen X-X, Zeng M-X, Cai D, Zhou H-H, Wang Y-J, Liu Z (2023) Correlation between APOE4 gene and gut microbiota in Alzheimer’s disease. Benef Microbes 14(4):349–360CrossRef
Zurück zum Zitat Chudzik A, Orzyłowska A, Rola R, Stanisz GJ (2021) Probiotics, prebiotics and postbiotics on mitigation of depression symptoms: modulation of the brain–gut–microbiome axis. Biomolecules 11(7):1000CrossRefPubMedPubMedCentral Chudzik A, Orzyłowska A, Rola R, Stanisz GJ (2021) Probiotics, prebiotics and postbiotics on mitigation of depression symptoms: modulation of the brain–gut–microbiome axis. Biomolecules 11(7):1000CrossRefPubMedPubMedCentral
Zurück zum Zitat D’Argenio V, Sarnataro D (2021) Probiotics, prebiotics and their role in Alzheimer’s disease. Neural Regen Res 16(9):1768–1769CrossRefPubMedCentral D’Argenio V, Sarnataro D (2021) Probiotics, prebiotics and their role in Alzheimer’s disease. Neural Regen Res 16(9):1768–1769CrossRefPubMedCentral
Zurück zum Zitat Den H, Dong X, Chen M, Zou Z (2020) Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer’s disease or mild cognitive impairment—a meta-analysis of randomized controlled trials. Aging (albany, NY) 12(4):4010CrossRefPubMed Den H, Dong X, Chen M, Zou Z (2020) Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer’s disease or mild cognitive impairment—a meta-analysis of randomized controlled trials. Aging (albany, NY) 12(4):4010CrossRefPubMed
Zurück zum Zitat Dinan TG, Stanton C, Cryan JF (2013) Psychobiotics: a novel class of psychotropic. Biol Psychiat 74(10):720–726CrossRefPubMed Dinan TG, Stanton C, Cryan JF (2013) Psychobiotics: a novel class of psychotropic. Biol Psychiat 74(10):720–726CrossRefPubMed
Zurück zum Zitat Distrutti E, O’Reilly J-A, McDonald C, Cipriani S, Renga B, Lynch MA et al (2014) Modulation of intestinal microbiota by the probiotic VSL# 3 resets brain gene expression and ameliorates the age-related deficit in LTP. PLoS ONE 9(9):e106503CrossRefPubMedPubMedCentral Distrutti E, O’Reilly J-A, McDonald C, Cipriani S, Renga B, Lynch MA et al (2014) Modulation of intestinal microbiota by the probiotic VSL# 3 resets brain gene expression and ameliorates the age-related deficit in LTP. PLoS ONE 9(9):e106503CrossRefPubMedPubMedCentral
Zurück zum Zitat Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E et al (2015) Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18(7):965–977CrossRefPubMedPubMedCentral Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E et al (2015) Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 18(7):965–977CrossRefPubMedPubMedCentral
Zurück zum Zitat Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L et al (2004) Behavioral symptoms in mild cognitive impairment. Neurology 62(7):1199–1201CrossRefPubMed Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L et al (2004) Behavioral symptoms in mild cognitive impairment. Neurology 62(7):1199–1201CrossRefPubMed
Zurück zum Zitat Fredua-Agyeman M, Stapleton P, Basit AW, Gaisford S (2017) Microcalorimetric evaluation of a multi-strain probiotic: interspecies inhibition between probiotic strains. J Funct Foods 36:357–361CrossRef Fredua-Agyeman M, Stapleton P, Basit AW, Gaisford S (2017) Microcalorimetric evaluation of a multi-strain probiotic: interspecies inhibition between probiotic strains. J Funct Foods 36:357–361CrossRef
Zurück zum Zitat Ibrahim A, Ali RAR, Manaf MRA, Ahmad N, Tajurruddin FW, Qin WZ et al (2020) Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson’s disease: a randomised controlled trial. PLoS ONE 15(12):e0244680CrossRefPubMedPubMedCentral Ibrahim A, Ali RAR, Manaf MRA, Ahmad N, Tajurruddin FW, Qin WZ et al (2020) Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson’s disease: a randomised controlled trial. PLoS ONE 15(12):e0244680CrossRefPubMedPubMedCentral
Zurück zum Zitat Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J et al (2011) Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry 26(5):473–482CrossRefPubMed Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J et al (2011) Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry 26(5):473–482CrossRefPubMed
Zurück zum Zitat Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K (2019) Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: a randomized clinical trial. Clin Nutr 38(2):522–528CrossRefPubMed Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K (2019) Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: a randomized clinical trial. Clin Nutr 38(2):522–528CrossRefPubMed
Zurück zum Zitat Li X, Hu D, Tian Y, Song Y, Hou Y, Sun L et al (2020) Protective effects of a novel Lactobacillus rhamnosus strain with probiotic characteristics against lipopolysaccharide-induced intestinal inflammation in vitro and in vivo. Food Funct 11(7):5799–5814CrossRefPubMed Li X, Hu D, Tian Y, Song Y, Hou Y, Sun L et al (2020) Protective effects of a novel Lactobacillus rhamnosus strain with probiotic characteristics against lipopolysaccharide-induced intestinal inflammation in vitro and in vivo. Food Funct 11(7):5799–5814CrossRefPubMed
Zurück zum Zitat McFarland LV (2021) Efficacy of single-strain probiotics versus multi-strain mixtures: systematic review of strain and disease specificity. Dig Dis Sci 66(3):694–704CrossRefPubMed McFarland LV (2021) Efficacy of single-strain probiotics versus multi-strain mixtures: systematic review of strain and disease specificity. Dig Dis Sci 66(3):694–704CrossRefPubMed
Zurück zum Zitat Missotten P, Squelard G, Ylieff M, Di Notte D, Paquay L, De Lepeleire J et al (2008) Relationship between quality of life and cognitive decline in dementia. Dement Geriatr Cogn Disord 25(6):564–572CrossRefPubMed Missotten P, Squelard G, Ylieff M, Di Notte D, Paquay L, De Lepeleire J et al (2008) Relationship between quality of life and cognitive decline in dementia. Dement Geriatr Cogn Disord 25(6):564–572CrossRefPubMed
Zurück zum Zitat Mohammadi G, Dargahi L, Peymani A, Mirzanejad Y, Alizadeh SA, Naserpour T et al (2019) The effects of probiotic formulation pretreatment (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) on a lipopolysaccharide rat model. J Am Coll Nutr 38(3):209–217CrossRefPubMed Mohammadi G, Dargahi L, Peymani A, Mirzanejad Y, Alizadeh SA, Naserpour T et al (2019) The effects of probiotic formulation pretreatment (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) on a lipopolysaccharide rat model. J Am Coll Nutr 38(3):209–217CrossRefPubMed
Zurück zum Zitat Musa NH, Mani V, Lim SM, Vidyadaran S, Majeed ABA, Ramasamy K (2017) Lactobacilli-fermented cow’s milk attenuated lipopolysaccharide-induced neuroinflammation and memory impairment in vitro and in vivo. J Dairy Res 84(4):488–495CrossRefPubMed Musa NH, Mani V, Lim SM, Vidyadaran S, Majeed ABA, Ramasamy K (2017) Lactobacilli-fermented cow’s milk attenuated lipopolysaccharide-induced neuroinflammation and memory impairment in vitro and in vivo. J Dairy Res 84(4):488–495CrossRefPubMed
Zurück zum Zitat Nandi A, Counts N, Chen S, Seligman B, Tortorice D, Vigo D et al (2022) Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: a value of statistical life approach. EClinicalMedicine 51:101580CrossRefPubMedPubMedCentral Nandi A, Counts N, Chen S, Seligman B, Tortorice D, Vigo D et al (2022) Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: a value of statistical life approach. EClinicalMedicine 51:101580CrossRefPubMedPubMedCentral
Zurück zum Zitat Oelschlaeger TA (2010) Mechanisms of probiotic actions—a review. Int J Med Microbiol 300(1):57–62CrossRefPubMed Oelschlaeger TA (2010) Mechanisms of probiotic actions—a review. Int J Med Microbiol 300(1):57–62CrossRefPubMed
Zurück zum Zitat Peters K, Rockwood K, Black S, Bouchard R, Gauthier S, Hogan D et al (2006) Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics. Neurology 66(4):523–528CrossRefPubMed Peters K, Rockwood K, Black S, Bouchard R, Gauthier S, Hogan D et al (2006) Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics. Neurology 66(4):523–528CrossRefPubMed
Zurück zum Zitat Rodes L, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C et al (2013) Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol 23(4):518–526CrossRefPubMed Rodes L, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C et al (2013) Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol 23(4):518–526CrossRefPubMed
Zurück zum Zitat Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer’s disease. Lancet (london, England) 388(10043):505–517CrossRefPubMed Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer’s disease. Lancet (london, England) 388(10043):505–517CrossRefPubMed
Zurück zum Zitat Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE et al (2021) Alzheimer’s disease. The Lancet 397(10284):1577–1590CrossRef Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE et al (2021) Alzheimer’s disease. The Lancet 397(10284):1577–1590CrossRef
Zurück zum Zitat Selvarajah D, Wilkinson ID, Davies J, Gandhi R, Tesfaye S (2011) Central nervous system involvement in diabetic neuropathy. Curr DiabRep 11(4):310–322 Selvarajah D, Wilkinson ID, Davies J, Gandhi R, Tesfaye S (2011) Central nervous system involvement in diabetic neuropathy. Curr DiabRep 11(4):310–322
Zurück zum Zitat Tekin S, Fairbanks LA, O’Connor S, Rosenberg S, Cummings JL (2001) Activities of daily living in Alzheimer’s disease: neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry 9(1):81–86CrossRefPubMed Tekin S, Fairbanks LA, O’Connor S, Rosenberg S, Cummings JL (2001) Activities of daily living in Alzheimer’s disease: neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry 9(1):81–86CrossRefPubMed
Zurück zum Zitat Zhan X, Stamova B, Sharp FR (2018) Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer’s disease brain: a review. Front Aging Neurosci 10:42CrossRefPubMedPubMedCentral Zhan X, Stamova B, Sharp FR (2018) Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer’s disease brain: a review. Front Aging Neurosci 10:42CrossRefPubMedPubMedCentral
Zurück zum Zitat Zhan Y, Al-Nusaif M, Ding C, Zhao L, Dong C (2023) The potential of the gut microbiome for identifying Alzheimer’s disease diagnostic biomarkers and future therapies. Front Neurosci 17:1130730CrossRefPubMedPubMedCentral Zhan Y, Al-Nusaif M, Ding C, Zhao L, Dong C (2023) The potential of the gut microbiome for identifying Alzheimer’s disease diagnostic biomarkers and future therapies. Front Neurosci 17:1130730CrossRefPubMedPubMedCentral
Zurück zum Zitat Zhang R, Miller RG, Gascon R, Champion S, Katz J, Lancero M et al (2009) Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 206(1–2):121–124CrossRefPubMed Zhang R, Miller RG, Gascon R, Champion S, Katz J, Lancero M et al (2009) Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 206(1–2):121–124CrossRefPubMed
Zurück zum Zitat Zhang X-X, Tian Y, Wang Z-T, Ma Y-H, Tan L, Yu J-T (2021) The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimer’s Dis 8:313–321 Zhang X-X, Tian Y, Wang Z-T, Ma Y-H, Tan L, Yu J-T (2021) The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimer’s Dis 8:313–321
Metadaten
Titel
The effects of probiotic supplements on oxidative stress and inflammation in subjects with mild and moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled study
verfasst von
Camellia Akhgarjand
Zahra Vahabi
Sakineh Shab-Bidar
Aliarash Anoushirvani
Kurosh Djafarian
Publikationsdatum
06.02.2024
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 2/2024
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-023-01427-2

Weitere Artikel der Ausgabe 2/2024

Inflammopharmacology 2/2024 Zur Ausgabe